BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has expanded distribution of the Quell Wearable Pain Relief device to The Grommet, a unique online product launch platform. "The Quell technology immediately stood out as a unique innovation that would appeal to our
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) will unveil innovative enhancements to its Quell ® Wearable Pain Relief Technology™ at the 2016 CES Event January 6-9 in Las Vegas . CES is the largest consumer technology event and has served as the launch pad for innovators and
BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today reported growing media coverage of the Company's innovative Quell ® Wearable Pain Relief Technology™. During the past two months, Quell has been featured on network television affiliates in New York , San Francisco , Philadelphia ,
Shares of Common Stock and Listed Warrants Have Begun Trading on a Split-Adjusted Basis on The NASDAQ Capital Market BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today confirmed that it has consummated a one-for-four reverse split of its common stock.
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be participating in the Benchmark Micro Cap Discovery One-On-One Conference at the Palmer House Hilton in Chicago, IL on Thursday, December
Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on December 2, 2015 BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced a one-for-four reverse split of its common stock effective as of Tuesday, December 1, 2015 .
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the 8 th annual LD Micro Main Event at the Luxe Sunset Bel Air Hotel in Los Angeles, CA on December 3, 2015 . Dr.
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,173,581. The patent covers the core technology deployed in the DPNCheck device. The claims cover the novel integrated design of the hand-held
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central , New York, NY on November
BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it was granted the American Podiatric Medical Association (APMA) Seal of Approval for its Quell Wearable Pain Relief device. "The APMA Seal of Approval is awarded after a rigorous scientific review by a group of APMA
